Journal of Clinical Oncology, Vol 11, 1132-1143, Copyright © 1993 by American Society of Clinical Oncology

ARTICLES

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

WP Peters, M Ross, JJ Vredenburgh, B Meisenberg, LB Marks, E Winer, J Kurtzberg, RC Bast Jr, R Jones and E Shpall
Department of Medicine, Duke University Medical Center, Durham, NC 27710.

PURPOSE: We studied high-dose cyclophosphamide, cisplatin, and carmustine (CPA/cDDP/BCNU) with autologous bone marrow support (ABMS) as consolidation after standard-dose adjuvant chemotherapy treatment of primary breast cancer involving 10 or more axillary lymph nodes. PATIENTS AND METHODS: One hundred two women with stage IIA, IIB, IIIA, or IIIB breast cancer involving 10 or more lymph nodes at surgery were registered; 85 were eligible, treated, and assessable. Patients were treated with four cycles of standard-dose cyclophosphamide, doxorubicin, and fluorouracil (CAF), followed by high-dose CPA/cDDP/BCNU with ABMS. RESULTS: Actuarial event-free survival for the study patients at a median follow-up of 2.5 years is 72% (95% confidence interval, 56% to 82%). Comparison to three historical or concurrent Cancer and Leukemia Group B (CALGB) adjuvant chemotherapy trials selected for similar patients showed event-free survival at 2.5 years to be between 38% and 52%. Therapy-related mortality was 12%; pulmonary toxicity of variable severity occurred in 31% of patients. Quality-of-life evaluations indicate that patients are functioning well without major impairments. CONCLUSION: High-dose consolidation with CPA/cDDP/BCNU and ABMS after standard-dose CAF results in a decreased frequency of relapse in patients with high-risk primary breast cancer compared with historical series at the median follow-up of 2.5 years. Evaluation in a prospective, randomized trial is warranted and currently underway.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. R. Zander, C. Schmoor, N. Kroger, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. E. Berdel, M. Koenigsmann, E. Thiel, et al. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up Ann. Onc., June 1, 2008; 19(6): 1082 - 1089. [Abstract] [Full Text] [PDF]

				T.-A. Nguyen, M. Tychopoulos, F. Bichat, C. Zimmermann, J.-P. Flinois, M. Diry, E. Ahlberg, M. Delaforge, L. Corcos, P. Beaune, et al. Improvement of Cyclophosphamide Activation by CYP2B6 Mutants: From in Silico to ex Vivo Mol. Pharmacol., April 1, 2008; 73(4): 1122 - 1133. [Abstract] [Full Text] [PDF]

				C. Buijs, S. Rodenhuis, C. M. Seynaeve, Q. G.C.M. van Hoesel, E. van der Wall, W. J.M. Smit, M. A. Nooij, E. Voest, P. Hupperets, E. M. TenVergert, et al. Prospective Study of Long-Term Impact of Adjuvant High-Dose and Conventional-Dose Chemotherapy on Health-Related Quality of Life J. Clin. Oncol., December 1, 2007; 25(34): 5403 - 5409. [Abstract] [Full Text] [PDF]

				P. D. Jacobson, R. A. Rettig, and W. M. Aubry Litigating the Science of Breast Cancer Treatment Journal of Health Politics Policy and Law, October 1, 2007; 32(5): 785 - 818. [Abstract] [PDF]

				R. Diallo-Danebrock, E. Ting, O. Gluz, A. Herr, S. Mohrmann, H. Geddert, A. Rody, K.-L. Schaefer, S. E. Baldus, A. Hartmann, et al. Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose-Dense Chemotherapy Clin. Cancer Res., January 15, 2007; 13(2): 488 - 497. [Abstract] [Full Text] [PDF]

				W. P. Petros, P. J. Hopkins, S. Spruill, G. Broadwater, J. J. Vredenburgh, O. M. Colvin, W. P. Peters, R. B. Jones, J. Hall, and J. R. Marks Associations Between Drug Metabolism Genotype, Chemotherapy Pharmacokinetics, and Overall Survival in Patients With Breast Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6117 - 6125. [Abstract] [Full Text] [PDF]

				D. A. Stewart, A. H. G. Paterson, J. D. Ruether, J. Russell, P. Craighead, M. Smylie, and J. Mackey High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study Ann. Onc., September 1, 2005; 16(9): 1463 - 1468. [Abstract] [Full Text] [PDF]

				R. C. Coombes, A. Howell, M. Emson, C. Peckitt, C. Gallagher, C. Bengala, A. Tres, R. Welch, P. Lawton, R. Rubens, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial Ann. Onc., May 1, 2005; 16(5): 726 - 734. [Abstract] [Full Text] [PDF]

				W. P. Peters, G. L. Rosner, J. J. Vredenburgh, E. J. Shpall, M. Crump, P. G. Richardson, M. W. Schuster, L. B. Marks, C. Cirrincione, L. Norton, et al. Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13 J. Clin. Oncol., April 1, 2005; 23(10): 2191 - 2200. [Abstract] [Full Text] [PDF]

				A. Schneeweiss, I. Diel, M. Hensel, S. Kaul, H.-P. Sinn, K. Unnebrink, C. Rudlowski, I. Lauschner, F. Schuetz, G. Egerer, et al. Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy Ann. Onc., November 1, 2004; 15(11): 1627 - 1632. [Abstract] [Full Text] [PDF]

				R. C. F. Leonard, M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, et al. Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial J Natl Cancer Inst, July 21, 2004; 96(14): 1076 - 1083. [Abstract] [Full Text] [PDF]

				A.R. Zander, N. Kroger, C. Schmoor, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. Schultze, W.E. Berdel, M. Koenigsmann, et al. High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Support Compared With Standard-Dose Chemotherapy in Breast Cancer Patients With 10 or More Positive Lymph Nodes: First Results of a Randomized Trial J. Clin. Oncol., June 15, 2004; 22(12): 2273 - 2283. [Abstract] [Full Text] [PDF]

				Y. Nieto, S. Nawaz, E. J. Shpall, S. I. Bearman, J. Murphy, and R. B. Jones Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy Clin. Cancer Res., April 15, 2004; 10(8): 2609 - 2617. [Abstract] [Full Text] [PDF]

				M. A. Qureshi, R. E. Girgis, H. K. Dandapantula, J. Abrams, and A. O. Soubani Increased Exhaled Nitric Oxide Following Autologous Peripheral Hematopoietic Stem-Cell Transplantation: A Potential Marker of Idiopathic Pneumonia Syndrome Chest, January 1, 2004; 125(1): 281 - 287. [Abstract] [Full Text] [PDF]

				Y. Brandberg, H. Michelson, B. Nilsson, C. Bolund, B. Erikstein, P. Hietanen, S. Kaasa, J. Nilsson, T. Wiklund, N. Wilking, et al. Quality of Life in Women With Breast Cancer During the First Year After Random Assignment to Adjuvant Treatment With Marrow-Supported High-Dose Chemotherapy With Cyclophosphamide, Thiotepa, and Carboplatin or Tailored Therapy With Fluorouracil, Epirubicin, and Cyclophosphamide: Scandinavian Breast Group Study 9401 J. Clin. Oncol., October 1, 2003; 21(19): 3659 - 3664. [Abstract] [Full Text] [PDF]

				S. Rodenhuis, M. Bontenbal, L. V.A.M. Beex, J. Wagstaff, D. J. Richel, M. A. Nooij, E. E. Voest, P. Hupperets, H. van Tinteren, H. L. Peterse, et al. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer N. Engl. J. Med., July 3, 2003; 349(1): 7 - 16. [Abstract] [Full Text] [PDF]

				M. S. Tallman, R. Gray, N. J. Robert, C. F. LeMaistre, C. K. Osborne, W. P. Vaughan, W. J. Gradishar, T. M. Pisansky, J. Fetting, E. Paietta, et al. Conventional Adjuvant Chemotherapy with or without High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in High-Risk Breast Cancer N. Engl. J. Med., July 3, 2003; 349(1): 17 - 26. [Abstract] [Full Text] [PDF]

				A. M. Farese, T. J. MacVittie, L. Roskos, and R. B. Stead Hematopoietic Recovery Following Autologous Bone Marrow Transplantation in a Nonhuman Primate: Effect of Variation in Treatment Schedule with PEG-rHuMGDF Stem Cells, January 1, 2003; 21(1): 79 - 89. [Abstract] [Full Text] [PDF]

				K. S. Bhalla and R. J. Folz Idiopathic Pneumonia Syndrome after Syngeneic Bone Marrow Transplant in Mice Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1579 - 1589. [Abstract] [Full Text] [PDF]

				A. M. Abushamaa, T. A. Sporn, and R. J. Folz Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L336 - L345. [Abstract] [Full Text] [PDF]

				H G. Welch and J. Mogielnicki Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer BMJ, May 4, 2002; 324(7345): 1088 - 1092. [Full Text] [PDF]

				W. P. Petros, G. Broadwater, D. Berry, R. B. Jones, J. J. Vredenburgh, C. J. Gilbert, J. P. Gibbs, O. M. Colvin, and W. P. Peters Association of High-dose Cyclophosphamide, Cisplatin, and Carmustine Pharmacokinetics with Survival, Toxicity, and Dosing Weight in Patients with Primary Breast Cancer Clin. Cancer Res., March 1, 2002; 8(3): 698 - 705. [Abstract] [Full Text] [PDF]

				M. S. Aapro Adjuvant Therapy of Primary Breast Cancer: A Review of Key Findings from the 7th International Conference, St. Gallen, February 2001 Oncologist, August 1, 2001; 6(4): 376 - 385. [Abstract] [Full Text] [PDF]

				R. B. Weiss, G. G. Gill, and C. A. Hudis An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications J. Clin. Oncol., June 1, 2001; 999(1): 1 - 8. [Abstract] [Full Text]

				R. B. Weiss, G. G. Gill, and C. A. Hudis An On-Site Audit of the South African Trial of High-Dose Chemotherapy for Metastatic Breast Cancer and Associated Publications J. Clin. Oncol., June 1, 2001; 19(11): 2771 - 2777. [Abstract] [Full Text] [PDF]

				A. Recht, S. B. Edge, L. J. Solin, D. S. Robinson, A. Estabrook, R. E. Fine, G. F. Fleming, S. Formenti, C. Hudis, J. J. Kirshner, et al. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1539 - 1569. [Abstract] [Full Text] [PDF]

				J.A. Sosman, P. Stiff, S.M. Moss, P. Sorokin, B. Martone, R. Bayer, K. van Besien, S. Devine, W. Stock, D. Peace, et al. Pilot Trial of Interleukin-2 With Granulocyte Colony-Stimulating Factor for the Mobilization of Progenitor Cells in Advanced Breast Cancer Patients Undergoing High-Dose Chemotherapy: Expansion of Immune Effectors Within the Stem-Cell Graft and Post-Stem-Cell Infusion J. Clin. Oncol., February 1, 2001; 19(3): 634 - 644. [Abstract] [Full Text] [PDF]

				R. D. Baynes, C. Hamm, R. Dansey, J. Klein, L. Cassells, C. Karanes, E. Abella, and W. P. Peters Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting Clin. Chem., August 1, 2000; 46(8): 1239 - 1251. [Abstract] [Full Text] [PDF]

				A. Patnaik, J. MacKinnon, P. Goss, T. Nagy, K. Stewart, A. Keating, and M. Crump Phase I/II Trial of Cyclophosphamide, Mitoxantrone, and Escalated Doses of Carboplatin Supported by Peripheral-Blood Stem Cells in Women With Metastatic Breast Cancer J. Clin. Oncol., June 12, 2000; 18(12): 2363 - 2368. [Abstract] [Full Text] [PDF]

				G. N. Hortobagyi, A. U. Buzdar, R. L. Theriault, V. Valero, D. Frye, D. J. Booser, F. A. Holmes, S. Giralt, I. Khouri, B. Andersson, et al. Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma J Natl Cancer Inst, February 2, 2000; 92(3): 225 - 233. [Abstract] [Full Text] [PDF]

				W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer Oncologist, February 1, 2000; 5(1): 1 - 13. [Abstract] [Full Text]

				K. S. BHALLA, S. W. WILCZYNSKI, A. M. ABUSHAMAA, W. P. PETROS, C. S. MCDONALD, J. S. LOFTIS, N. J. CHAO, J. J. VREDENBURGH, and R. J. FOLZ Pulmonary Toxicity of Induction Chemotherapy Prior to Standard or High-dose Chemotherapy with Autologous Hematopoietic Support Am. J. Respir. Crit. Care Med., January 1, 2000; 161(1): 17 - 25. [Abstract] [Full Text]

				R. B. Weiss The Randomized Trials of Dose-Intensive Therapy for Breast Cancer: What Do They Mean for Patient Care and Where Do We Go From Here? Oncologist, December 1, 1999; 4(6): 450 - 458. [Abstract] [Full Text]

				D. A. Rizzieri, J. J. Vredenburgh, R. Jones, M. Ross, E. J. Shpall, A. Hussein, G. Broadwater, D. Berry, W. P. Petros, C. Gilbert, et al. Prognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous Stem-Cell Support J. Clin. Oncol., October 1, 1999; 17(10): 3064 - 3074. [Abstract] [Full Text] [PDF]

				D. Adkins, R. Brown, K. Trinkaus, R. Maziarz, S. Luedke, C. Freytes, B. Needles, D. Wienski, P. Fracasso, T. Pluard, et al. Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer J. Clin. Oncol., July 1, 1999; 17(7): 2006 - 2006. [Abstract] [Full Text] [PDF]

				R. J. Schilder, S. Johnson, J. Gallo, S. Kindsfather, B. Rogers, M. A. Bookman, M. M. Millenson, M. Boente, N. Rosenblum, S. Litwin, et al. Phase I Trial of Multiple Cycles of High-Dose Chemotherapy Supported by Autologous Peripheral-Blood Stem Cells J. Clin. Oncol., July 1, 1999; 17(7): 2198 - 2198. [Abstract] [Full Text] [PDF]

				K. H. Cowan, J. A. Moscow, H. Huang, J. A. Zujewski, J. O'Shaughnessy, B. Sorrentino, K. Hines, C. Carter, E. Schneider, G. Cusack, et al. Paclitaxel Chemotherapy after Autologous Stem-Cell Transplantation and Engraftment of Hematopoietic Cells Transduced with a Retrovirus Containing the Multidrug Resistance Complementary DNA (MDR1) in Metastatic Breast Cancer Patients Clin. Cancer Res., July 1, 1999; 5(7): 1619 - 1628. [Abstract] [Full Text] [PDF]

				J. A. Moscow, H. Huang, C. Carter, K. Hines, J. Zujewski, G. Cusack, C. Chow, D. Venzon, B. Sorrentino, Y. Chiang, et al. Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy Blood, July 1, 1999; 94(1): 52 - 61. [Abstract] [Full Text] [PDF]

				A. Recht, R. Gray, N. E. Davidson, B. L. Fowble, L. J. Solin, F. J. Cummings, G. Falkson, H. C. Falkson, S. G. Taylor IV, and D. C. Tormey Locoregional Failure 10 Years After Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen Without Irradiation: Experience of the Eastern Cooperative Oncology Group J. Clin. Oncol., June 1, 1999; 17(6): 1689 - 1689. [Abstract] [Full Text] [PDF]

				R. J. Folz Mechanisms of Lung Injury after Bone Marrow Transplantation Am. J. Respir. Cell Mol. Biol., June 1, 1999; 20(6): 1097 - 1099. [Full Text]

				R. L. Basser, L. B. To, J. P. Collins, C. G. Begley, D. Keefe, J. Cebon, J. Bashford, S. Durrant, J. Szer, D. Kotasek, et al. Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up J. Clin. Oncol., January 1, 1999; 17(1): 82 - 82. [Abstract] [Full Text] [PDF]

				C. Hudis, A. Seidman, J. Baselga, G. Raptis, D. Lebwohl, T. Gilewski, M. Moynahan, N. Sklarin, D. Fennelly, J. P.A. Crown, et al. Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy J. Clin. Oncol., January 1, 1999; 17(1): 93 - 93. [Abstract] [Full Text] [PDF]

				S. Subramanyan and M. J. Kennedy Breast Cancer: High-Dose Therapy Oncologist, October 1, 1998; 3(5): 289 - 299. [Abstract] [Full Text]

				F. J. Esteva and G. N. Hortobagyi Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer Oncologist, October 1, 1998; 3(5): 300 - 313. [Abstract] [Full Text]

				Integrating Economic Analysis Into Cancer Clinical Trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook J Natl Cancer Inst Monographs, August 1, 1998; 1998(24): 1 - 28. [Full Text]

				C. C. Gotay and M. Wilson Use of Quality-of-Life Outcome Assessments in Current Cancer Clinical Trials Eval Health Prof, June 1, 1998; 21(2): 157 - 178. [Abstract] [PDF]

				D. J. Gaskin, J. Kong, N. J. Meropol, K. R. Yabroff, C. Weaver, and K. A. Schulman Treatment Choices by Seriously III Patients: The Health Stock Risk Adjustment Model Med Decis Making, January 1, 1998; 18(1): 84 - 94. [Abstract] [PDF]

				C. A. Hudis and L. Norton Adjuvant Drug Treatment for Resectable Breast Cancer Oncologist, December 1, 1997; 2(6): 351 - 358. [Abstract] [Full Text] [PDF]

				E. J. Shpall, C. F. LeMaistre, K. Holland, E. Ball, R. B. Jones, R. Saral, C. Jacobs, S. Heimfeld, R. Berenson, and R. Champlin A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose Chemotherapy Blood, December 1, 1997; 90(11): 4313 - 4320. [Abstract] [Full Text] [PDF]

				L.B. To, D.N. Haylock, P.J. Simmons, and C.A. Juttner The Biology and Clinical Uses of Blood Stem Cells Blood, April 1, 1997; 89(7): 2233 - 2258. [Full Text] [PDF]

				G. Somlo, I. Sniecinski, T. Odom-Maryon, B. Nowicki, W. Chow, V. Hamasaki, L. Leong, K. Margolin, R. Morgan Jr, J. Raschko, et al. Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer Blood, March 1, 1997; 89(5): 1521 - 1528. [Abstract] [Full Text] [PDF]

				S. W. WILCZYNSKI, J. J. ERASMUS, W. P. PETROS, J. J. VREDENBURGH, and R. J. FOLZ Delayed Pulmonary Toxicity Syndrome following High-dose Chemotherapy and Bone Marrow Transplantation for Breast Cancer Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 565 - 573. [Abstract] [Full Text]

				B. Brockstein and S. Williams High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow Stem Cells, January 1, 1996; 14(1): 79 - 89. [Abstract]

				K. J. Krause, C. M. Cutler, I. S. Udvarhelyi, W. Winkenwerder, J. K. Erban, K. M. Templeton, J. R. Wingard, V. Khanna, W. P. Peters, and M. C. Rogers Variations in Insurance Coverage for Autologous Bone Marrow Transplantation for Breast Cancer N. Engl. J. Med., August 4, 1994; 331(5): 329 - 331. [Full Text]

				T L Holyoake and I M Franklin Bone marrow transplants from peripheral blood BMJ, July 2, 1994; 309(6946): 4 - 5. [Full Text]

				W. P. Peters and M. C. Rogers Variation in Approval by Insurance Companies of Coverage for Autologous Bone Marrow Transplantation for Breast Cancer N. Engl. J. Med., February 17, 1994; 330(7): 473 - 477. [Abstract] [Full Text]

				J. A. O'Shaughnessy and K. H. Cowan Dose-Intensive Therapy for Breast Cancer JAMA, November 3, 1993; 270(17): 2089 - 2092. [Abstract] [PDF]